These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27237059)

  • 21. R2* Relaxation Affects Pharmacokinetic Analysis of Dynamic Contrast-Enhanced MRI in Cancer and Underestimates Treatment Response at 7 T.
    Kim J; Moestue SA; Bathen TF; Kim E
    Tomography; 2019 Sep; 5(3):308-319. PubMed ID: 31572792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding Relative Biological Effectiveness and Clinical Outcome of Prostate Cancer Therapy Using Particle Irradiation: Analysis of Tumor Control Probability With the Modified Microdosimetric Kinetic Model.
    Besuglow J; Tessonnier T; Mein S; Eichkorn T; Haberer T; Herfarth K; Abdollahi A; Debus J; Mairani A
    Int J Radiat Oncol Biol Phys; 2024 Aug; 119(5):1545-1556. PubMed ID: 38423224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multimodal approach to assess tumour vasculature and potential treatment effect with DCE-US and DCE-MRI quantification in CWR22 prostate tumour xenografts.
    Arteaga-Marrero N; Rygh CB; Mainou-Gomez JF; Nylund K; Roehrich D; Heggdal J; Matulaniec P; Gilja OH; Reed RK; Svensson L; Lutay N; Olsen DR
    Contrast Media Mol Imaging; 2015; 10(6):428-37. PubMed ID: 26010530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative pharmacokinetic analysis of high-temporal-resolution dynamic contrast-enhanced MRI to differentiate the normal-appearing pituitary gland from pituitary macroadenoma.
    Kamimura K; Nakajo M; Yoneyama T; Bohara M; Nakanosono R; Fujio S; Iwanaga T; Nickel MD; Imai H; Fukukura Y; Yoshiura T
    Jpn J Radiol; 2020 Jul; 38(7):649-657. PubMed ID: 32162178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dynamic contrast-enhanced MRI for automatic detection of foci of residual or recurrent disease after prostatectomy.
    Parra NA; Orman A; Padgett K; Casillas V; Punnen S; Abramowitz M; Pollack A; Stoyanova R
    Strahlenther Onkol; 2017 Jan; 193(1):13-21. PubMed ID: 27761612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Dispersion MRI for Improved Prostate Cancer Diagnosis in a Multicenter Study.
    Turco S; Lavini C; Heijmink S; Barentsz J; Wijkstra H; Mischi M
    AJR Am J Roentgenol; 2018 Nov; 211(5):W242-W251. PubMed ID: 30346837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of liver fibrosis using pharmacokinetic parameters of dynamic contrast-enhanced magnetic resonance imaging.
    Li Z; Sun J; Chen L; Huang N; Hu P; Hu X; Han G; Zhou Y; Bai W; Niu T; Yang X
    J Magn Reson Imaging; 2016 Jul; 44(1):98-104. PubMed ID: 26707910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-response curves for MRI-detected radiation-induced temporal lobe reactions in patients after proton and carbon ion therapy: Does the same RBE-weighted dose lead to the same biological effect?
    Gillmann C; Lomax AJ; Weber DC; Jäkel O; Karger CP
    Radiother Oncol; 2018 Jul; 128(1):109-114. PubMed ID: 29459152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of arterial input function (AIF) on quantitative prostate dynamic contrast-enhanced (DCE) MRI and zonal prostate anatomy.
    Ziayee F; Müller-Lutz A; Gross J; Quentin M; Ullrich T; Heusch P; Arsov C; Rabenalt R; Albers P; Antoch G; Wittsack HJ; Schimmöller L
    Magn Reson Imaging; 2018 Nov; 53():28-33. PubMed ID: 29902565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative sensitivities of DCE-MRI pharmacokinetic parameters to arterial input function (AIF) scaling.
    Li X; Cai Y; Moloney B; Chen Y; Huang W; Woods M; Coakley FV; Rooney WD; Garzotto MG; Springer CS
    J Magn Reson; 2016 Aug; 269():104-112. PubMed ID: 27288764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative diffusion-weighted imaging and dynamic contrast-enhanced characterization of the index lesion with multiparametric MRI in prostate cancer patients.
    Yuan Q; Costa DN; Sénégas J; Xi Y; Wiethoff AJ; Rofsky NM; Roehrborn C; Lenkinski RE; Pedrosa I
    J Magn Reson Imaging; 2017 Mar; 45(3):908-916. PubMed ID: 27442039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
    Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
    Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early responses assessment of neoadjuvant chemotherapy in nasopharyngeal carcinoma by serial dynamic contrast-enhanced MR imaging.
    Zheng D; Yue Q; Ren W; Liu M; Zhang X; Lin H; Lai G; Chen W; Chan Q; Chen Y
    Magn Reson Imaging; 2017 Jan; 35():125-131. PubMed ID: 27587228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing MRI scan time in the computation of pharmacokinetic parameters (K(trans) ) in breast cancer diagnosis.
    Jena A; Mehta SB; Taneja S
    J Magn Reson Imaging; 2013 Sep; 38(3):573-9. PubMed ID: 23349046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic contrast-enhanced case-control analysis in 3T MRI of prostate cancer can help to characterize tumor aggressiveness.
    Sanz-Requena R; Martí-Bonmatí L; Pérez-Martínez R; García-Martí G
    Eur J Radiol; 2016 Nov; 85(11):2119-2126. PubMed ID: 27776667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Feasibility and value of quantitative dynamic contrast enhancement MR imaging in the evaluation of sinonasal tumors.
    Xian J; Du H; Wang X; Yan F; Zhang Z; Hao H; Zhao B; Tong Y; Zhang J; Han D
    Chin Med J (Engl); 2014; 127(12):2259-64. PubMed ID: 24931238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamic contrast-enhanced magnetic resonance imaging measurements in renal cell carcinoma: effect of region of interest size and positioning on interobserver and intraobserver variability.
    Braunagel M; Radler E; Ingrisch M; Staehler M; Schmid-Tannwald C; Rist C; Nikolaou K; Reiser MF; Notohamiprodjo M
    Invest Radiol; 2015 Jan; 50(1):57-66. PubMed ID: 25260094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MRI before and after external beam intensity-modulated radiotherapy of patients with prostate cancer: the feasibility of monitoring of radiation-induced tissue changes using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence.
    Franiel T; Lüdemann L; Taupitz M; Böhmer D; Beyersdorff D
    Radiother Oncol; 2009 Nov; 93(2):241-5. PubMed ID: 19748143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate Cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI.
    Hötker AM; Mazaheri Y; Zheng J; Moskowitz CS; Berkowitz J; Lantos JE; Pei X; Zelefsky MJ; Hricak H; Akin O
    Eur Radiol; 2015 Sep; 25(9):2665-72. PubMed ID: 25820537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modeling secondary cancer risk ratios for proton versus carbon ion beam therapy: A comparative study based on the local effect model.
    Hufnagl A; Johansson G; Siegbahn A; Durante M; Friedrich T; Scholz M
    Med Phys; 2022 Aug; 49(8):5589-5603. PubMed ID: 35717591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.